{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:49:46Z","timestamp":1777474186609,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3\u00a0years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Subject satisfaction remained relatively stable from the first to the last injection visit. At 3\u00a0years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3\u00a0years. Mean\u2009\u00b1\u2009SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59\u2009\u00b1\u200913.04 at baseline to 24.49\u2009\u00b1\u200912.43 at 3\u00a0years (mean\u2009\u00b1\u2009SD reduction from baseline of \u2212\u00a06.97\u2009\u00b1\u200911.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3\u00a0years.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite objective clinical improvements over 3\u00a0years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-019-09527-2","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T14:03:23Z","timestamp":1568037803000},"page":"3038-3046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["How satisfied are cervical dystonia patients after 3\u00a0years of botulinum toxin type A treatment? Results from a prospective, long-term observational study"],"prefix":"10.1007","volume":"266","author":[{"name":"the INTEREST IN CD2 study group","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-3973","authenticated-orcid":false,"given":"Carlo","family":"Colosimo","sequence":"first","affiliation":[]},{"given":"David","family":"Charles","sequence":"additional","affiliation":[]},{"given":"Vijay P.","family":"Misra","sequence":"additional","affiliation":[]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[]},{"given":"Savary","family":"Om","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"issue":"Suppl 1","key":"9527_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","volume":"26","author":"M Stacy","year":"2008","unstructured":"Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23\u201342","journal-title":"Neurol Clin"},{"issue":"2","key":"9527_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6(2):119\u2013126. \nhttps:\/\/doi.org\/10.1002\/mds.870060206","journal-title":"Mov Disord"},{"key":"9527_CR3","doi-asserted-by":"publisher","DOI":"10.7916\/D80C4TGJ","author":"G Defazio","year":"2013","unstructured":"Defazio G, Jankovic J, Giel JL, Papapetropoulos S (2013) Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y). \nhttps:\/\/doi.org\/10.7916\/D80C4TGJ","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"9527_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72(5):608\u2013614","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"9527_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.clineuro.2008.09.023","volume":"111","author":"T Pekmezovic","year":"2009","unstructured":"Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111(2):161\u2013164. \nhttps:\/\/doi.org\/10.1016\/j.clineuro.2008.09.023","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"9527_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W, Austrian Botulinum T, Dystonia Study G","year":"2002","unstructured":"Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W, Austrian Botulinum T, Dystonia Study G (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249(7):842\u2013846. \nhttps:\/\/doi.org\/10.1007\/s00415-002-0733-1","journal-title":"J Neurol"},{"issue":"4","key":"9527_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-014-7586-2","volume":"262","author":"C Comella","year":"2015","unstructured":"Comella C, Bhatia K (2015) An international survey of patients with cervical dystonia. J Neurol 262(4):1. \nhttps:\/\/doi.org\/10.1007\/s00415-014-7586-2","journal-title":"J Neurol"},{"issue":"1","key":"9527_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Sole J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18(1):5\u201318. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2010.03042.x","journal-title":"Eur J Neurol"},{"key":"9527_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 86:1\u20139","journal-title":"Neurology"},{"issue":"5","key":"9527_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/archneur.1990.00530050070014","volume":"47","author":"M Jahanshahi","year":"1990","unstructured":"Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47(5):548\u2013552","journal-title":"Arch Neurol"},{"issue":"12 Suppl 5","key":"9527_CR11","first-page":"S2","volume":"55","author":"M Stacy","year":"2000","unstructured":"Stacy M (2000) Idiopathic cervical dystonia: an overview. Neurology 55(12 Suppl 5):S2\u20138","journal-title":"Neurology"},{"issue":"4","key":"9527_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265\u2013273. \nhttps:\/\/doi.org\/10.1007\/s12640-012-9314-y","journal-title":"Neurotox Res"},{"issue":"5","key":"9527_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463\u2013466. \nhttps:\/\/doi.org\/10.1179\/174313209X405137","journal-title":"Neurol Res"},{"issue":"2","key":"9527_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/toxins5020249","volume":"5","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, Jankovic J (2013) Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 5(2):249\u2013266. \nhttps:\/\/doi.org\/10.3390\/toxins5020249","journal-title":"Toxins (Basel)"},{"issue":"3","key":"9527_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","volume":"12","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163\u2013170. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2004.01053.x","journal-title":"Eur J Neurol"},{"issue":"3","key":"9527_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19(3):303\u2013308. \nhttps:\/\/doi.org\/10.1002\/mds.10659","journal-title":"Mov Disord"},{"key":"9527_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/B978-0-444-52014-2.00037-9","volume":"100","author":"ML Evatt","year":"2011","unstructured":"Evatt ML, Freeman A, Factor S (2011) Adult-onset dystonia. Handb Clin Neurol 100:481\u2013511. \nhttps:\/\/doi.org\/10.1016\/B978-0-444-52014-2.00037-9","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"9527_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X","volume":"15","author":"A Brashear","year":"2000","unstructured":"Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15(1):150\u2013153","journal-title":"Mov Disord"},{"issue":"4","key":"9527_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/toxins5040776","volume":"5","author":"CE Gill","year":"2013","unstructured":"Gill CE, Manus ND, Pelster MW, Cook JA, Title W, Molinari AL, Charles D (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5(4):776\u2013783. \nhttps:\/\/doi.org\/10.3390\/toxins5040776","journal-title":"Toxins (Basel)"},{"issue":"3","key":"9527_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jval.2012.03.1385","volume":"15","author":"E Basch","year":"2012","unstructured":"Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15(3):401\u2013403. \nhttps:\/\/doi.org\/10.1016\/j.jval.2012.03.1385","journal-title":"Value Health"},{"key":"9527_CR21","doi-asserted-by":"publisher","first-page":"c2921","DOI":"10.1136\/bmj.c2921","volume":"340","author":"J Speight","year":"2010","unstructured":"Speight J, Barendse SM (2010) FDA guidance on patient reported outcomes. BMJ 340:c2921. \nhttps:\/\/doi.org\/10.1136\/bmj.c2921","journal-title":"BMJ"},{"issue":"2","key":"9527_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s00415-017-8698-2","volume":"265","author":"VP Misra","year":"2018","unstructured":"Misra VP, Colosimo C, Charles D, Chung TM, Maisonobe P, Om S (2018) INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J Neurol 265(2):402\u2013409. \nhttps:\/\/doi.org\/10.1007\/s00415-017-8698-2","journal-title":"J Neurol"},{"key":"9527_CR23","unstructured":"International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiological practices (GPP), June 2015. \nhttps:\/\/www.pharmacoepi.org\/resources\/guidelines_08027.cfm"},{"key":"9527_CR24","unstructured":"Consky E, Lang AE (1994) Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York."},{"issue":"8501","key":"9527_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"JK Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501):245\u2013247","journal-title":"Lancet"},{"issue":"3","key":"9527_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15(3):419\u2013423. \nhttps:\/\/doi.org\/10.3111\/13696998.2011.653726","journal-title":"J Med Econ"},{"issue":"2","key":"9527_CR27","doi-asserted-by":"publisher","first-page":"e0170988","DOI":"10.1371\/journal.pone.0170988","volume":"12","author":"J Birkhauer","year":"2017","unstructured":"Birkhauer J, Gaab J, Kossowsky J, Hasler S, Krummenacher P, Werner C, Gerger H (2017) Trust in the health care professional and health outcome: a meta-analysis. PLoS ONE 12(2):e0170988. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0170988","journal-title":"PLoS ONE"},{"key":"9527_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11648\/ajns.s.2018070301.25","volume":"10","author":"A Mitsi","year":"2018","unstructured":"Mitsi A, Kourakos M, Poulimenakou G, Latsou D, Sarris M (2018) Therapeutic relationship and quality of life in chronic diseases. Am J Nurs Sci 10:1. \nhttps:\/\/doi.org\/10.11648\/ajns.s.2018070301.25","journal-title":"Am J Nurs Sci"},{"issue":"4","key":"9527_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ctcp.2005.05.005","volume":"11","author":"MJ Leach","year":"2005","unstructured":"Leach MJ (2005) Rapport: a key to treatment success. Complement Ther Clin Pract 11(4):262\u2013265. \nhttps:\/\/doi.org\/10.1016\/j.ctcp.2005.05.005","journal-title":"Complement Ther Clin Pract"},{"issue":"7","key":"9527_CR30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/mds.23709","volume":"26","author":"DJ Kuyper","year":"2011","unstructured":"Kuyper DJ, Parra V, Aerts S, Okun MS, Kluger BM (2011) Nonmotor manifestations of dystonia: a systematic review. Mov Disord 26(7):1206\u20131217. \nhttps:\/\/doi.org\/10.1002\/mds.23709","journal-title":"Mov Disord"},{"key":"9527_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.03.002","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Trosch R, Suarez G, Johnson J, Marchese D, Comella C (2018) Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat Disord. \nhttps:\/\/doi.org\/10.1016\/j.parkreldis.2018.03.002","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"9527_CR32","first-page":"225","volume":"27","author":"JJ Ferreira","year":"2012","unstructured":"Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27(4):225\u2013230","journal-title":"Funct Neurol"}],"updated-by":[{"DOI":"10.1007\/s00415-019-09549-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09527-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:17:45Z","timestamp":1599520665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09527-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9527"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09527-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-019-09549-w","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article How satisfied are cervical dystonia patients after 3\u00a0years of botulinum toxin type A treatment?","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Prof C Colosimo reports consultancy for Ipsen, Merz, Abbvie, BIAL, Zambon and UCB. Vanderbilt University receives income from Abbott, Allergan, Boston Scientific, Ipsen, Lundbeck, Merz, Medtronic, and US WorldMeds for research or educational programs led by Dr D Charles. Dr D Charles receives income from Allergan, Ipsen, Revance, US WorldMeds, and the Alliance for Patient Access for education or consulting services. Dr VP Misra report consultancy for Ipsen. P Maisonobe & Dr S Om are Ipsen employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in compliance with the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP). Independent Ethics Committee\/Institutional Review Board approval was obtained prior to each centre initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"Written informed consent was obtained prior to subject enrolment and performance of any study procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}